98138-75-1

Usage

General Description

6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine is a chemical compound with the molecular formula C7H6ClN3O. It is a pyrazolopyrimidine derivative, which has been studied for its potential pharmaceutical applications. 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine is a chlorinated and methoxylated derivative of pyrazolo[3,4-d]pyrimidine, and it has been investigated for its anti-cancer and anti-inflammatory properties. It has also been studied as a potential precursor for the synthesis of biologically active compounds. 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine is a valuable chemical intermediate with potential applications in the pharmaceutical industry.

Upstream product

• 124-41-4 sodium methylate 
• 42754-96-1 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine 
• 2465-59-0 oxypurinol 
• 67-56-1 methanol 
• 50270-27-4 2,4,6-trichloropyrimidine-5-carbaldehyde 

Downstream Products

• 7251-92-5 6-chloro-N-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 5417-78-7 6-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-amine 

Relevant academic research and scientific papers

SHP2 INHIBITORS AND USES THEREOF

Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.

SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS

The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5', R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.

SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

Discovery of a pyrrolopyrimidine (JH-II-127), a highly potent, selective, and brain penetrant LRRK2 inhibitor

Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson's disease (PD) patients and may represent an attractive therapeutic target. Here we report a 2-anilino-4-methylamino-5-chloropyrrolopyrimidine, JH-II-127 (18

N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS

N-(4-(Azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.